Biogen

Youtube Subscribe

Open: 278.93 Close: 277.97 Change: -0.96

Is Biogen Company Inc Stock a good investment? This what an AI found.

This document will help you to evaluate Biogen without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, approval, drug, BIIB, FDA, Leqembi, stock, and the …

Concept Map

Semantic Network

Stock Summary

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, AVonEX, PLE.

Today's Summary

Biogen (NASDAQ: BIIB) stock is up 0.5% premarket on Monday. Leqembi won a coveted standard approval nod from the U.S. FDA granted accelerated approval of the drug earlier this year.

Today's News

RBC Capital Maintains Biogen (BIIB) Outperform Recommendation. Goldman Sachs Downgrades Engagesmart (ESMT) from Buy to Neutral. Biogen shares slid more than 3% by Friday market close and are down nearly 10% over the past month. Needham Reaffirms their Buy Rating on Biogen. FDA granted full approval to Biogen and Eisais anti-amyloid antibody drug Leqembi. The approval led to a drop in Biogen stock, in part due to the FDAs warning about potential side effects such as brain swelling and hemorrhaging. US FDA grants standard approval of Eisai/Biogen Alzheimers drug. Leqembi won a coveted standard approval nod from the U.S. FDA granted accelerated approval of the drug earlier this year. Biogen (NASDAQ: BIIB ) stock is in the news Friday after the company got approval from the U.S. The approval comes after it reported results from a Phase 3 clinical trial of the drug. With this, Biogen will soon be ready to market its new treatment. H.c. Wainwright remains a Buy on Biogen (BIIB) TipRanks lists the best-performing stocks on Tipranks. Phase III clinical trials were ongoing in September 2016, but were canceled in March 2019. Biogen halted development of the medication after preliminary data from two phase III trials suggested it would not meet the primary endpoint. Treatment using aducanumab is estimated to cost US$56,000 per year. Biogen (NASDAQ: BIIB) got some great news last week as the Food and Drug Administration (FDA) approved the companys Alzheimers drug Leqembi. Decision on the drug follows controversy over the FDAs handling of a previous Alzheimer drug, Aduhelm, which was also developed by Biogen and Eisai. Biogen stock is up 0.5% premarket on Monday. Leqembi is the first approved treatment to slow progression of Alzheimers disease. Eisai and Biogen are seeking approval in Japan, the European Union, China, Canada, Great Britain.

Stock Profile

"Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts."

Keywords

Are looking for the most relevant information about Biogen? Investor spend a lot of time searching for information to make investment decisions in Biogen. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Biogen are: Biogen, approval, drug, BIIB, FDA, Leqembi, stock, and the most common words in the summary are: biogen, best, stock, alzheimers, drug, fda, approval, . One of the sentences in the summary was: FDA granted accelerated approval of the drug earlier this year.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biogen #best #stock #alzheimers #drug #fda #approval.

Read more →

Youtube Subscribe

---